Ingenuity Systems Announces Multi-Year Agreement with Boehringer Ingelheim
News Jun 04, 2008
Ingenuity Systems announced the signing of a four year agreement with Boehringer Ingelheim for Ingenuity Pathway Analysis (IPA). IPA will be used throughout the Boehringer Ingelheim research and development organization to unlock novel insights from experimental data and as a general tool for biological search and exploration.
The agreement provides global access for Boehringer Ingelheim research scientists to access to the recently released IPA 6, which includes new biological and chemical content, in addition to Path Designer, an award-winning set of tools that more clearly communicates information about networks and pathways.
"We are pleased at this opportunity to become a strategic partner in Boehringer Ingelheim's research and development efforts," stated Jake Leschly, CEO, Ingenuity Systems.
Scientists have found that bowel cancer is actually five distinct diseases, with different biological characteristics which affect how they respond to drugs. The new genetic test can diagnose a person’s specific type of bowel cancer in a matter of hours and help tailor treatments to each individual disease.READ MORE
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE